DB06493InvestigationalSmall molecule
Velafermin was a novel investigational protein therapeutic, also known as fibroblast growth factor-20 (FGF-20), which promotes both epithelial and mesenchymal cell proliferation in vitro and has demonstrated activity in multiple... Velafermin was investigated as a potential therapy for the prevention and treatment of oral mucositis by fostering the regeneration and repair of the cells lining the gastrointestinal tract.
- Primary indication
- Investigated for use/treatment in adverse effects (chemotherapy).Curator reviewed
- Also known as
- FIBROBLAST GROWTH FACTOR 20 (HUMAN RECOMBINANT CG53135) · RECOMBINANT HUMAN FIBROBLAST GROWTH FACTOR-20
- Code names
- CG53135 · CG-53135-05
Resolves to
Compound
Clinical / RWD
What you can answer from here — as of July 18, 2023
Which companies are running trials of Velafermin, in which indications and phases, and which of those programs are still active?
Create a free account or log in to explore the full data card.
Create Account